GO:0008495 protoheme IX farnesyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008495 (protoheme IX farnesyltransferase activity) catalyzes the conversion of protoheme IX to heme O by adding a farnesyl group from farnesyl diphosphate.
• The enzyme is also known as heme O synthase and is encoded by the COX10 gene in humans.
• Loss of COX10 function impairs mitochondrial complex IV assembly and causes focal segmental glomerulosclerosis with interferon response.
• In Staphylococcus aureus, protoheme IX farnesyltransferase activity is required for cytolytic toxin production, linking heme O synthesis to bacterial virulence.
• The enzyme is a target for antimicrobial and antimalarial drug development.
• Research on this activity uses CRISPR knockout, point mutation, and knock-in models to dissect its role in mitochondrial and infectious diseases.
Description
Protoheme IX farnesyltransferase activity (GO:0008495) is a molecular function that catalyzes the attachment of a farnesyl group to protoheme IX, yielding heme O and diphosphate. This modification is a critical step in the biosynthesis of heme A, the essential cofactor of cytochrome c oxidase (complex IV) in the mitochondrial respiratory chain. Because heme A is required for the assembly and function of complex IV, the enzyme—encoded by COX10 in humans—is central to mitochondrial energy metabolism. Beyond mitochondria, the same activity is found in bacteria such as Staphylococcus aureus, where it supports the production of cytolytic toxins and contributes to virulence. In pathogenic fungi, the enzyme is a target for natural antimicrobials. Given its roles in mitochondrial disease, infection, and drug discovery, protoheme IX farnesyltransferase activity is a compelling subject for functional genomics and therapeutic research.
protoheme IX farnesyltransferase activity At A Glance
| GO ID | GO:0008495 |
|---|---|
| GO term | protoheme IX farnesyltransferase activity |
| Ontology | molecular_function |
| Synonym | haem O synthase activity; heme A:farnesyltransferase activity; heme O synthase activity; protohaem IX farnesyltransferase activity |
| Major function | Catalyzes the farnesylation of protoheme IX to form heme O, a step in heme A biosynthesis |
| Representative gene | COX10 (human), ctaB (bacteria), cox10 (fungi) |
| Substrates | Protoheme IX and (2E,6E)-farnesyl diphosphate |
| Products | Heme O and diphosphate |
| Localization | Mitochondrial inner membrane in eukaryotes; bacterial cytoplasmic membrane |
What Is GO:0008495?
Protoheme IX farnesyltransferase activity is defined as the catalysis of the reaction: protoheme IX + (2E,6E)-farnesyl diphosphate + H2O = heme O + diphosphate. In simpler terms, it is the enzyme activity that adds a farnesyl tail to protoheme IX, converting it into heme O, a precursor of heme A.
Why Is protoheme IX farnesyltransferase activity Important in Cell Biology?
Protoheme IX farnesyltransferase activity is essential for the biosynthesis of heme A, which is the prosthetic group of cytochrome c oxidase (complex IV). Consequently, defects in this activity impair mitochondrial respiration and have been linked to human disease, including focal segmental glomerulosclerosis and interferonopathies. The enzyme is also a virulence factor in Staphylococcus aureus, where it is required for the production of cytolytic toxins. In agriculture and food safety, inhibition of the fungal enzyme by natural preservatives such as perillaldehyde prevents food spoilage. Moreover, the enzyme is being explored as a drug target in malaria parasites. Thus, understanding this activity has broad implications for mitochondrial medicine, infectious disease, and antimicrobial development.
• Required for heme A biosynthesis and mitochondrial complex IV assembly.
• Loss of function causes focal segmental glomerulosclerosis and innate immune activation.
• Supports cytolytic toxin production in Staphylococcus aureus, impacting bacterial virulence.
• Target of natural antimicrobials against food spoilage fungi such as Aspergillus flavus.
• Potential drug target in malaria chemotherapy.
• Involved in mitochondrial dysfunction-linked kidney disease.
• Enables studies of mitochondrial genetics and respiratory chain disorders.
• Provides a model for protein prenylation mechanisms.
• Links heme metabolism to cellular stress and immune responses.
• Facilitates development of CRISPR-based disease models for therapeutic screening.
What Happens During protoheme IX farnesyltransferase activity?
Substrate binding and farnesyl transfer
In simple terms: The enzyme grabs protoheme IX and a farnesyl molecule, then attaches the farnesyl group to the heme.
Protoheme IX farnesyltransferase binds protoheme IX and (2E,6E)-farnesyl diphosphate, catalyzing the transfer of the farnesyl moiety to the heme ring, releasing diphosphate and forming heme O. This reaction is a key step in the heme A biosynthetic pathway.
Heme O formation and downstream conversion
In simple terms: The product, heme O, is then modified further to become heme A, which is needed for energy production.
Heme O is subsequently converted to heme A by heme A synthase. Heme A is the essential cofactor for cytochrome c oxidase (complex IV), where it facilitates electron transfer and proton pumping.
Role in mitochondrial respiration
In simple terms: Without this enzyme, mitochondria cannot make the cofactor needed for the last step of energy generation.
In eukaryotes, protoheme IX farnesyltransferase (COX10) is located in the mitochondrial inner membrane. Its activity is required for the assembly and stability of complex IV; loss of COX10 leads to complex IV deficiency and mitochondrial dysfunction.
Bacterial and fungal counterparts
In simple terms: Bacteria and fungi have similar enzymes that help them produce toxins or survive.
In Staphylococcus aureus, the enzyme (encoded by ctaB) is necessary for the production of cytolytic toxins, and its inhibition reduces virulence. In the food spoilage fungus Aspergillus flavus, the enzyme is targeted by the natural preservative perillaldehyde, which inhibits fungal growth.
Key Genes Involved in GO:0008495 protoheme IX farnesyltransferase activity
The following genes encode proteins that either possess protoheme IX farnesyltransferase activity or are directly involved in its pathway and regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| COX10 | Human protoheme IX farnesyltransferase; converts protoheme IX to heme O | Mutations cause complex IV deficiency, FSGS, and interferon response |
| COX15 | Heme A synthase; converts heme O to heme A | Downstream of COX10; mutations cause complex IV deficiency |
| ctaB | Bacterial protoheme IX farnesyltransferase in Staphylococcus aureus | Required for cytolytic toxin production; virulence factor |
| cox10 (fungal) | Fungal homolog in Aspergillus flavus | Target of perillaldehyde; food spoilage prevention |
| PfCOX10 | Plasmodium falciparum homolog | Potential antimalarial drug target |
| SDHA | Complex II subunit; unrelated but used as control in mitochondrial studies | Reference gene for mitochondrial function |
| ATP5A1 | Complex V subunit; mitochondrial marker | Control for mitochondrial integrity |
| MT-CO1 | Mitochondrial-encoded complex IV subunit | Marker of complex IV assembly |
| NDUFA9 | Complex I subunit | Control for respiratory chain studies |
| UQCRC2 | Complex III subunit | Control for mitochondrial function |
| HSP60 | Mitochondrial chaperone | Marker of mitochondrial stress |
| IFNB1 | Interferon beta 1 | Induced upon COX10 loss; links to innate immunity |
| ISG15 | Interferon-stimulated gene 15 | Upregulated in COX10 knockout; interferon signature |
| STAT1 | Signal transducer and activator of transcription 1 | Mediates interferon response in COX10 deficiency |
| PPARGC1A | PGC-1alpha; mitochondrial biogenesis regulator | Modulates mitochondrial adaptation |
| MFN2 | Mitofusin 2; mitochondrial fusion | Affects mitochondrial dynamics |
| DNM1L | Drp1; mitochondrial fission | Regulates mitochondrial morphology |
| TFAM | Mitochondrial transcription factor A | Maintains mtDNA; affects respiratory chain |
How Is protoheme IX farnesyltransferase activity Regulated?
The expression and activity of protoheme IX farnesyltransferase are regulated at multiple levels. In eukaryotes, COX10 is a nuclear-encoded gene whose transcription is controlled by mitochondrial biogenesis regulators such as PGC-1alpha. The enzyme's activity depends on the availability of substrates, including protoheme IX and farnesyl diphosphate, and on the mitochondrial inner membrane environment. In bacteria, ctaB expression is influenced by oxygen availability and respiratory chain demands. Additionally, the enzyme can be inhibited by small molecules, as shown for perillaldehyde in fungi.
protoheme IX farnesyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| COX10 | Focal segmental glomerulosclerosis; interferonopathy; complex IV deficiency | COX10 knockout mouse; patient-derived fibroblasts |
| COX10 | Leigh syndrome spectrum | Induced pluripotent stem cells with COX10 mutations |
| ctaB | Staphylococcus aureus virulence | ctaB deletion mutant in S. aureus; infection models |
| cox10 (fungal) | Aspergillus flavus food spoilage | Fungal knockout and perillaldehyde treatment |
| PfCOX10 | Malaria | Plasmodium falciparum culture with enzyme inhibitors |
Mitochondrial disease and focal segmental glomerulosclerosis
Deletion of COX10, the gene encoding protoheme IX farnesyltransferase, causes focal segmental glomerulosclerosis and a robust interferon response in mouse models. This links the enzyme to mitochondrial dysfunction and innate immune activation in kidney disease. Patients with COX10 mutations may present with Leigh syndrome spectrum disorders due to complex IV deficiency.
Infectious disease and virulence
In Staphylococcus aureus, protoheme IX farnesyltransferase activity is required for the production of cytolytic toxins, making it a potential target for antivirulence therapies. In malaria parasites, the enzyme is essential for heme A biosynthesis and is considered a drug target.
Food spoilage and antimicrobials
The fungal enzyme in Aspergillus flavus is inhibited by the natural preservative perillaldehyde, which prevents food spoilage. This highlights the enzyme as a target for food safety interventions.
From protoheme IX farnesyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of COX10 cause mitochondrial dysfunction? | COX10 knockout cell lines (e.g., HEK293, HeLa) |
| What is the role of COX10 in kidney disease? | COX10 conditional knockout mouse (podocyte-specific) |
| How does COX10 mutation affect complex IV assembly? | Patient-derived fibroblasts with COX10 point mutations |
| Can we rescue COX10 deficiency? | Knock-in of wild-type COX10 in knockout cells |
| Is ctaB required for S. aureus virulence? | ctaB deletion mutant in S. aureus |
| Can perillaldehyde inhibit fungal growth? | Aspergillus flavus cox10 knockout and overexpression |
How to Study the protoheme IX farnesyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotypes | Study COX10 in mitochondrial disease |
| RNA-seq | Transcriptional changes | Interferon signature in COX10 knockout |
| Proteomics | Protein abundance and interactions | Complex IV assembly |
| Blue-native PAGE | Respiratory chain supercomplexes | Mitochondrial dysfunction |
| HPLC/mass spectrometry | Heme O and heme A levels | Enzyme activity quantification |
| Bacterial genetics | Virulence factor production | S. aureus ctaB mutants |
| Fungal inhibition assays | Growth and spoilage | Aspergillus flavus with perillaldehyde |
| Antimalarial drug assays | Parasite survival | Plasmodium falciparum |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes required for protoheme IX farnesyltransferase activity or its downstream effects. For example, knockout of COX10 in human cells leads to complex IV deficiency and interferon response, which can be monitored by RNA-seq.
RNA-seq and transcriptomics
RNA sequencing of COX10 knockout cells reveals upregulation of interferon-stimulated genes, providing insights into innate immune activation. This method helps define the transcriptional consequences of loss of protoheme IX farnesyltransferase activity.
Proteomics and complexome profiling
Proteomic analysis of mitochondrial fractions can assess the assembly state of complex IV and the abundance of heme A biosynthetic enzymes. Blue-native PAGE followed by mass spectrometry is useful to detect complex IV assembly defects in COX10 mutants.
Metabolic labeling and heme analysis
Heme O and heme A levels can be measured by HPLC or mass spectrometry after metabolic labeling. These methods directly quantify the enzymatic activity of protoheme IX farnesyltransferase in cells and tissues.
How CRISPR Can Be Used to Study GO:0008495 protoheme IX farnesyltransferase activity
Knockout
CRISPR knockout of COX10 in human cell lines abolishes protoheme IX farnesyltransferase activity, leading to complex IV deficiency and interferon response. These models are valuable for studying mitochondrial disease mechanisms.
Point Mutation
Introducing patient-specific point mutations in COX10 via CRISPR base editing or homology-directed repair allows researchers to dissect the functional impact of missense variants on enzyme activity and complex IV assembly.
Knock-in
Knock-in of wild-type or tagged COX10 can rescue knockout phenotypes and enable affinity purification of the enzyme complex. This approach helps identify interacting proteins and regulatory partners.
Overexpression
Overexpression of COX10 or its bacterial homolog ctaB can increase heme O production and may enhance respiratory chain capacity. This is useful for biotechnological applications and for studying enzyme kinetics.
How EDITGENE Supports protoheme IX farnesyltransferase activity Research
Researchers studying protoheme IX farnesyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in mitochondrial function, bacterial virulence, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for protoheme IX farnesyltransferase activity research.
Frequently Asked Questions About protoheme IX farnesyltransferase activity
What is protoheme IX farnesyltransferase activity?
It is the enzyme activity that catalyzes the conversion of protoheme IX to heme O by adding a farnesyl group, encoded by GO:0008495.
What genes are involved in protoheme IX farnesyltransferase activity?
The main human gene is COX10; bacterial homologs include ctaB, and fungal homologs include cox10.
What diseases are associated with protoheme IX farnesyltransferase deficiency?
Deficiency causes complex IV deficiency, focal segmental glomerulosclerosis, and interferonopathies.
How is protoheme IX farnesyltransferase activity measured?
It can be measured by HPLC or mass spectrometry to quantify heme O production from protoheme IX.
Is protoheme IX farnesyltransferase a drug target?
Yes, it is a target for antimicrobials against fungi and parasites, and for antivirulence therapies against Staphylococcus aureus.
What is the role of COX10 in mitochondria?
COX10 is required for heme A biosynthesis and complex IV assembly in the mitochondrial respiratory chain.
Can CRISPR be used to study protoheme IX farnesyltransferase?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to study COX10 function and disease mechanisms.
What are the substrates of protoheme IX farnesyltransferase?
The substrates are protoheme IX and (2E,6E)-farnesyl diphosphate.
What is heme O?
Heme O is the product of protoheme IX farnesylation and a precursor to heme A, which is essential for cytochrome c oxidase.
Which organisms have protoheme IX farnesyltransferase?
The enzyme is found in humans, bacteria, fungi, and malaria parasites, among others.
Conclusion
Protoheme IX farnesyltransferase activity (GO:0008495) is a critical enzymatic step in heme A biosynthesis, with far-reaching implications for mitochondrial function, bacterial virulence, and eukaryotic stress responses. Its central role in complex IV assembly makes it a key player in mitochondrial disease, while its presence in pathogens offers opportunities for antimicrobial development. Continued research using CRISPR models and advanced omics will further illuminate its mechanisms and therapeutic potential.
References
- 1. Adam MP et al.. 1993. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.. PMID: 26425749
- 2. Fünfschilling U et al.. 2012. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.. Nature 485(7399):517-21 PMID: 22622581
- 3. Stevens E et al.. 2017. Cytolytic toxin production by Staphylococcus aureus is dependent upon the activity of the protoheme IX farnesyltransferase.. Sci Rep 7(1):13744 PMID: 29062030
- 4. Carney EF. 2018. A link between mitochondrial dysfunction and innate immune activation in FSGS.. Nat Rev Nephrol 14(12):721 PMID: 30327552
- 5. Zhuo Q et al.. 2024. Role of mitochondrial farnesyltransferase gene in the prevention of the food spoilage fungi Aspergillus flavus by the antimicrobial natural preservative perillaldehyde.. Food Microbiol 118:104422 PMID: 38049276
- 6. Baek JH et al.. 2018. Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon Response.. Am J Pathol 188(12):2745-2762 PMID: 30268775
- 7. Liñares GE et al.. 2007. Current status and progresses made in malaria chemotherapy.. Curr Med Chem 14(3):289-314 PMID: 17305534
